08 Aug Which BNP Better Predicts CV Events in Stable Coronary Heart Disease?
MedicalResearch.com Interview with:
Rakesh K. Mishra, MD
San Francisco Veterans Affairs Medical Center
San Francisco, CA 94121.
Medical Research: What are the main findings of the study?
Dr. Mishra: Increased levels of both BNP and NT-proBNP are associated with elevated risk of adverse cardiovascular events in patients with stable coronary artery disease. However, when added to existing clinical models of risk, NT-proBNP is superior to BNP for risk reclassification.
Medical Research: Were any of the findings unexpected?
Dr. Mishra: Prior literature has suggested that BNP and NT-proBNP are equivalent markers of risk in stable coronary artery disease. We, however, found that, though both B-type natriuretic peptides are associated with risk of adverse cardiovascular events, NT-proBNP performs better than BNP for risk classification.
Medical Research: What should clinicians and patients take away from your report?
Dr. Mishra: When determining risk of adverse cardiovascular events in stable coronary artery disease, both BNP and NT-proBNP enhance risk models consisting of clinical variables alone. However, NT-proBNP may be superior to BNP for risk classification.
Medical Research: What recommendations do you have for future research as a result of this study?
Dr. Mishra :Future research should determine whether the differences we noted between NT-proBNP and BNP in stable coronary disease also hold in other disease states such as acute coronary syndrome, asymptomatic severe aortic stenosis, chronic kidney disease, etc.